Home / Intelligence

  • All
  • Blog
  • Briefs
  • Case Studies
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Featured Topic
  • All
  • AIML
  • Analytics
  • APAC
  • Benchmarking
  • Biosimilars
  • CAR-T
  • Cell and Gene Therapy
  • Commercial Operations
  • Competitive Intelligence
  • Contract Analytics
  • Corporate Strategy
  • COVID-19
  • Data Management
  • Digital Therapeutics
  • Diversity
  • Emerging Life Sciences
  • Europe
  • Evidence Strategy (HEOR)
  • Field Force
  • Forecasting
  • Generative AI
  • Incentive Compensation
  • Inflation Reduction Act
  • Insights
  • International
  • LatAm
  • Launch and Brand Excellence
  • Learning and Development
  • Market Research
  • Marketing
  • MedTech
  • New Product Planning
  • NRDL
  • Omnichannel
  • Oncology
  • Patient Centricity
  • Patient Finding
  • Patient Services
  • Performance Tracking
  • Pricing and Access
  • Product Demos
  • Rare Disease
  • Real-World Evidence
  • Scientific Publications
  • Talent Acquisition and Retention
  • United States
  • Value Communication


Diversity in Clinical Trials: Evaluating Current Initiatives and the Impending Impact of the FDA’s Guidance

July 17, 2024 | 1:00 - 1:45 PM ET

Trinity’s Diversity, Equity & Inclusion (DEI) strategy team invites life sciences executives to join a lively discussion on recent research and developments in clinical trial diversity with a focus on racial and ethnic minorities.

Sign Up Now



Looking Ahead to the November Election and Beyond

August 14, 2024 | 1:00 - 2:00 PM ET


Making AI Real in Medical Affairs

Available On Demand

Scientific Publications

Assessing Healthcare Resource Utilization Across Segments of Obesity — A Retrospective Claims Study

Obesity is a disease that is caused and influenced by genes and the environment. Whether different etiologies or presentations of obesity result in homogeneous disease burden and/or cost is not well characterized. The objective is to determine whether there are distinct segments within the pool of patients who are obese that are differentiated by clinical characteristics, and quantify their healthcare resource utilization (direct healthcare costs [HCC]), using U.S. claims data. Authors Marissa Suh, Monica Fay, Amy McCagg, Ida Moeller, Scott…

Read Now

White Papers

How to Approach Asset Valuation in Pharma & Biotech:

Pharma and biotech companies are innovation drivers at the frontlines of research and development. To fund and support this promising science, there is a great need for partnerships and mergers and acquisitions (M&A) to drive the growth/pipeline of the industry. For these collaborative relationships to occur, understanding the value of a company’s underlying assets is of the utmost importance. Since Trinity’s founding, multiple pharma and biotech clients have relied on its expertise in forecast and valuing assets. These engagements have…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email